Vajdi, M., Safaei, E., Moeinolsadat, S., Mousavi, S., Seyedhosseini-Ghaheh, H., Abbasalizad-Farhangi, M., & Askari, G
GLP-1s, especially for new users, can upset the gastrointestinal system, causing nausea, vomiting, constipation, diarrhea, and abdominal pain
BPC-157 accelerates localized healing at injury sites and in the gut
GLP1 Medications Policy developments, coverage trends and implications for healthcare costs May 2026 GLP1 (glucagon-like peptide-1) receptor agonists have rapidly transformed the landscape of obesity and diabetes management
Photo Credit: Shutterstock GLP-1 Dropout Rates: Why So Many People Quit Despite the hype, real-world adherence to GLP-1 medications is surprisingly low
New evidence suggests trizepatide (Zepound/Mounjaro) produces the largest weight loss on average, outperforming semaglutide in trials